Stephanie Nahas

Associate Professor (initial appointment of Instructor)

Thomas Jefferson University

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Stephanie Nahas is an Associate Professor at Thomas Jefferson University in the United States. Her research focuses on migraine pathology, treatment effectiveness, and patient-centered care strategies. Recent publications include studies on the efficacy of various treatment options for migraine and an exploration of risk factors associated with disease progression. Her work contributes significantly to the understanding and management of migraine, particularly in older populations.

Articles (10)

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (2)

Hans-Christoph Diener

University of Duisburg-Essen Faculty of Medizin

GERMANY

View details

Richard B Lipton

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Stephanie Nahas

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Risk factors for migraine disease progression: a narrative review for a patient-centered approach

Persistence to anti-CGRP monoclonal antibodies and onabotulinumtoxinA among patients with migraine: a retrospective cohort study

The Safety of Celecoxib as an Acute Treatment for Migraine: A Narrative Review.

Optimized Acute Treatment of Migraine Is Associated With Greater Productivity in People With Migraine

Correction: Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies

Erenumab dosage for migraine prevention: An evidence‐based narrative review with recommendations

Beyond the Raskin Protocol: Ketamine, Lidocaine, and Other Therapies for Refractory Chronic Migraine

Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies

Cluster Headache and Other Trigeminal Autonomic Cephalalgias

Biomarkers in Migraine

Collaborators (2)

Hans-Christoph Diener

Richard B Lipton

Make your next move.